Melinta Therapeutics GudangMovies21 Rebahinxxi LK21

    Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.
    In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics. It was renamed Melinta Therapeutics in 2013.
    One of its products, delafloxacin (BAXDELA®), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006, was approved by the FDA in 2017.
    As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.
    Melinta also markets meropenem/vaborbactam (VABOMERE®) approved in 2017, and oritavancin (ORBACTIV®) approved in 2014.
    Melinta shredded off its discovery research team in late 2018.
    It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
    On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.
    In April 2020, it was transferred to affiliates of its creditor Deerfield Management.
    In 2023, Melinta achieved FDA approval for rezafungin (REZZAYO), an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.


    References




    External links


    Official website

Kata Kunci Pencarian:

melinta therapeuticsmelinta therapeutics stockmelinta therapeutics addressmelinta therapeutics pipelinemelinta therapeutics careersmelinta therapeutics revenuemelinta therapeutics headquartersmelinta therapeutics newsmelinta therapeutics logomelinta therapeutics parsippany nj
Homepage - Melinta

Homepage - Melinta

Melinta Therapeutics Announces Commercial Availability of KIMYRSA ...

Melinta Therapeutics Announces Commercial Availability of KIMYRSA ...

Melinta Therapeutics | LinkedIn

Melinta Therapeutics | LinkedIn

About Melinta - Melinta

About Melinta - Melinta

About Melinta - Melinta

About Melinta - Melinta

News - Melinta

News - Melinta

Melinta Therapeutics | citybiz

Melinta Therapeutics | citybiz

Melinta Therapeutics raises $67M - [Jcount.com]

Melinta Therapeutics raises $67M - [Jcount.com]

Our Impact - Melinta

Our Impact - Melinta

Our Impact - Melinta

Our Impact - Melinta

Our Impact - Melinta

Our Impact - Melinta

Melinta Therapeutics Office Photos | Glassdoor

Melinta Therapeutics Office Photos | Glassdoor

Search Results

melinta therapeutics

Daftar Isi

Homepage - Melinta

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data focused on Melinta’s portfolio of commercial and investigational stage products to be shared at Infectious Disease Week (IDWeek) 2024, Oct. 16-19, 2024 ...

Our Products - Melinta

Resources. How do we do it? With integrity. And by demonstrating an unsurpassed commitment to patients, one another and the business. We have a big impact while staying grounded in our patients.

About Melinta - Melinta

At Melinta, we are committed to ensuring that everything we do to achieve our mission is rooted in the highest standards of integrity and complies with the laws and regulations that govern our industry.

Join Us - Melinta

At Melinta, you will be part of a team that is passionate and dedicated to saving lives. Our team is focused on supporting our patients and customers by delivering innovative products.

News - Melinta

Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today, ten scientific presentations with data focused on Melinta’s portfolio of commercial and investigational stage products to be shared at Infectious Disease Week (IDWeek) 2024, Oct. 16-19, 2024 ...

Melinta Therapeutics and Venatorx Pharmaceuticals Announce …

Nov 9, 2023 · Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact.

Melinta Therapeutics Partners with BARDA to Advance Two FDA …

Jul 10, 2023 · Parsippany, NJ – Melinta Therapeutics, LLC (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced today a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to advance two antibiotics currently FDA-approved for adults, BAXDELA® (delafloxacin ...

Melinta Therapeutics Announces FDA Approval of KIMYRSA™ …

MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) — Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the treatment of adult patients with acute ...

Melinta Therapeutics & Cidara Therapeutics Announce …

Dec 5, 2023 · PARSIPPANY, NJ, and SAN DIEGO, CA — Dec 5, 2023 — Melinta Therapeutics, LLC and Cidara Therapeutics, Inc. (NASDAQ: CDTX) today announced the peer-reviewed publication of pooled data from two completed global clinical trials evaluating REZZAYO ® (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

MELINTA THERAPEUTICS ANNOUNCES COMMERCIAL …

PARSIPPANY, NJ, July 31, 2023 –Melinta Therapeutics, LLC today announced the availability of REZZAYO™ (rezafungin for injection), for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.